Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
An interventional clinical trial using oral nicotinamide riboside (NR) in hospitalized
patients with COVID-19 infection and acute kidney injury to determine the effect of NR on
whole blood nicotinamide adenine dinucleotide (NAD+) levels and to evaluate safety of the use
of NR.
Phase:
Phase 2
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)